Characterization of HGF/Met signaling in cell lines derived from urothelial carcinoma of the bladder

Cancers

Volumn 6, Issue 4, 2014, Pages 2313-2329

  Lee, Young H ^a   Apolo, Andrea B ^a   Agarwal, Piyush K ^a   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bladder cancer; Hepatocyte growth factor; Met; Tumor cell invasion; Tumor growth; Urothelial carcinoma

Indexed keywords

CABOZANTINIB; CRIZOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; TEPOTINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; CANCER CELL LINE; CANCER GROWTH; CARCINOGENICITY; CELL ACTIVATION; CELL ANCHORAGE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC50; INHIBITION KINETICS; LIMIT OF DETECTION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PREVALENCE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84925449125     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6042313     Document Type: Article

References (33)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2012, 62, 10-29.
2. Stein, J.P.; Lieskovsky, G.; Cote, R.; Groshen, S.; Feng, A.; Boyd, S.; Skinner, E.; Bochner, B.; Thangathurai, D.; Mikhail, M., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J. Clin. Oncol. 2001, 19, 666-675.
3. Von der Maase, H.; Sengelov, L.; Roberts, J.T.; Ricci, S.; Dogliotti, L., Oliver, T.; Moore, M.J.; Zimmermann, A.; Arning, M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005, 23, 4602-4608.
4. Botteman, M.F.; Pashos, C.L.; Redaelli, A.; Laskin, B.; Hauser, R. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003, 21, 1315-1330.
5. Cecchi, F.; Rabe, D.C.; Bottaro, D.P. Targeting the HGF/Met signaling pathway in cancer therapy. Expert. Opin. Ther. Targets 2012, 16, 553-752.
6. Yamamoto, N.; Mammadova, G.; Song, R.X.; Fukami, Y.; Sato, K. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J. Cell Sci. 2006, 119, 4623-4633.
7. Tamatani, T.; Hattori, K.; Iyer, A.; Tamatani, K.; Oyasu, R. Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro. Carcinogenesis 1999, 20, 957-962.
8. Inui, M.; Nishi, N.; Yasumoto, A.; Takenaka, I.; Miyanaka, H.; Matsumoto, K.; Nakamura, T.; Wada, F. Enhanced gene expression of transforming growth factor-alpha and c-met in rat urinary bladder cancer. Urol. Res. 1996, 24, 55-60.
9. Sanchez-Carbayo, M.; Socci, N.D.; Lozano, J.J.; Haab, B.B.; Cordon-Cardo, C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 2006, 168, 93-103.
10. Cheng, H.L.; Trink, B.; Tzai, T.S.; Liu, H.-S.; Chan, S.-H.; Ho, C.-L.; Sidransky, D.; Chow, N.-H. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation. J. Clin. Oncol. 2002, 20, 1544-1550.
11. Miyata, Y.; Sagara, Y.; Kanda, S.; Hayashi, T.; Kanetake, H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: Correlation with matrix metalloproteinase-2 and-7 and E-cadherin. Hum. Pathol. 2009, 40, 496-504.
12. Iyer, G.; Al-Ahmadie, H.; Schultz, N.; Hanrahan, A.J.; Ostrovnaya, I.; Balar, A.V.; Kim, P.H.; Lin, O.; Weinhold, N.; Sander, C., et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 2013, 31, 3133-3140.
13. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E., et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401-404.
14. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 2013, 6, doi:10.1126/scisignal.2004088.
15. Guo, G.; Sun, X.; Chen, C.; Wu, S.; Huang, P.; Li, Z.; Dean, M.; Huang, Y.; Jia, W.; Zhou, Q., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 2013, 45, 1459-1463.
16. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507, 315-322.
17. Experimental Cancer Therapeutics Targeting the Hepatocyte Growth Factor/Met Signaling Pathway. Available online: https://ccrod.cancer.gov/confluence/display/CCRHGF/Home (accessed on 20 October 2014).
18. Xu, H.; Stabile, L.P.; Gubish, C.T.; Gooding, W.E.; Grandis, J.R.; Siegfried, J.M. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin. Cancer Res. 2011, 17, 4425-4438.
19. Yamazaki, S.; Skaptason, J.; Romero, D.; Lee, J.H.; Zou, H.Y.; Christensen, J.G.; Koup, J.R.; Smith, J.B.; Koudriakova, T. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab. Dispos. 2008, 36, 1267-1274.
20. Zou, H.; Li, Q.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.J.; Kung, P., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67, 4408-4417.
21. Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 2011, 10, 2298-2308.
22. You, W.K.; Sennino, B.; Williamson, C.W.; Falcón, B.; Hashizume, H.; Yao, L.; Aftab, D.T.; McDonald, D.M. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011, 71, 4758-4768.
23. Sennino, B.; Ishiguro-Oonuma, T.; Wei, Y.; Naylor, R.M.; Williamson, C.W.; Bhagwandin, V.; Tabruyn, S.P.; You, W.; Chapman, H.A.; Christensen, J.G., et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012, 2, 270-287.
24. Nguyen, H.M.; Ruppender, N.; Zhang, X.; Brown, L.G.; Gross, T.S.; Morrissey, C.; Gulati, R.; Vessella, R.L.; Schimmoller, F.; Aftab, D.T., et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 2013, 8, e78881.
25. Bladt, F.; Faden, B.; Friese-Hamim, M.; Knuehl, C.; Wilm, C.; Fittschen, C.; Grädler, U.; Meyring, M.; Dorsch, D.; Jaehrling, F., et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin. Cancer Res. 2013, 19, 2941-2951.
26. McNeil, B.; Sorbellini, M.; Athauda, G.; Apolo, A.B.; Cecchi, F.; Athauda, G.; Cohen, B.; Giubellino, A.; Simpson, H.; Agarwal, P.K., et al. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. J. Trans. Med. 2014, 12, 199-205.
27. Coxon, A.; Rex, K.; Meyer, S.; Sun, J.; Sun, J.; Chen, Q.; Radinsky, R.; Kendall, R.; Burgess, T.L. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: C-Met-dependent tumors in animal models. Mol. Cancer Ther. 2009, 5, 1119-1125.
28. Li, B.; Kanamaru, H.; Noriki, S.; Fukuda, M.; Okada, K. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int. J. Urol. 1998, 5, 436-440.
29. Wang, P.; Nishitani, M.A.; Tanimoto, S.; Kishimoto, T.; Fukumori, T.; Takahashi, M.; Kanayama, H. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology 2007, 69, 780-784.
30. Rosen, E.M.; Joseph, A.; Jin, L.; Yao, Y.; Chau, M.T.; Fuchs, A.; Gomella, L.; Hastings, H.; Goldberg, I.D.; Weiss, G.H. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. J. Urol. 1997, 157, 72-78.
31. Chiba, S.; Tsuchiya, N.; Horikawa, Y.; Narita, S.; Inoue, T.; Akihama, S.; Saito, M.; Numakura, K.; Tsuruta, H.; Huang, M., et al. Functional mononucleotide repeat polymorphism in the promoter region of HGF is associated with risk and malignant aggressiveness of bladder cancer. Int. J. Oncol. 2014, 44, 678-684.
32. Apolo, A.B.; Lee, Y.H.; Cecchi, F.; Agrawal, P.K.; Parnes, H.; Khadar, K.; Summerell, A.; Gulley, J.L.; Compton, K.; Figg, W.D., et al. Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). J. Clin. Oncol. 2013, 31, 314.
33. Athauda, G.; Giubellino, A.; Coleman, J.A.; Horak, C.; Steeg, P.S.; Lee, M.; Trepel, J.; Wimberly, J.; Sun, J.; Coxon, A., et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin. Cancer Res. 2006, 12, 4154-4162.